Neurometrix Inc  

(Public, NASDAQ:NURO)   Watch this stock  
Find more results for NURO
2.32
0.00 (0.00%)
Real-time:   1:23PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.31 - 2.35
52 week 1.47 - 4.25
Open 2.31
Vol / Avg. 13,425.00/118,850.00
Mkt cap 13.79M
P/E     -
Div/yield     -
EPS -3.10
Shares 5.95M
Beta 1.37
Inst. own 18%
Apr 24, 2014
Q1 2014 NeuroMetrix Inc. Earnings Release - 9:30AM EDT - Add to calendar
Apr 24, 2014
Q1 2014 NeuroMetrix Inc. Earnings Conference Call - 8:00AM EDT - Add to calendar
Feb 13, 2014
Q4 2013 NeuroMetrix Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -264.14% -151.91%
Operating margin -98.23% -139.40%
EBITD margin - -136.55%
Return on average assets -144.93% -74.00%
Return on average equity -228.50% -109.86%
Employees 30 -
CDP Score - -

Address

62 4th Avenue
WALTHAM, MA 02451
United States - Map
+1-781-8909989 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NeuroMetrix, Inc. (NeuroMetrix) is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company is in the position to address these unmet needs through the development of medical devices. The Company intends to advance its objectives in the diabetic neuropathy market include: Driving Commercial Adoption of Products for Diabetic Neuropathy in the United States. The Company develops and market neurodiagnostic systems, which typically consists of a medical device plus single patient-use biosensors or electrodes.The Company�s NC-stat DPNCheck consists of an electronic hand-held device and a single patient use biosensor. More than 1.7 million patient studies have been performed using the Company's NC-stat technology and there have been approximately 6.3 million nerve tests, including nearly 700,000 sural nerve tests.

Officers and directors

Shai N. Gozani M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer, Secretary
Age: 48
Bio & Compensation  - Reuters
Thomas T. Higgins Chief Financial Officer, Senior Vice President, Treasurer
Age: 61
Bio & Compensation  - Reuters
Michael Williams Ph.D. Senior Vice President - Engineering, Chief Technology Officer
Age: 56
Bio & Compensation  - Reuters
Guy A Daniello Senior Vice President - Information Technology
Age: 68
Bio & Compensation  - Reuters
David Van Avermaete Director
Bio & Compensation  - Reuters
David E. Goodman M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Allen J. Hinkle M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Nancy E. Katz Independent Director
Age: 53
Bio & Compensation  - Reuters
Timothy R. Surgenor Independent Director
Age: 53
Bio & Compensation  - Reuters